Bio Screening Industry News

Plenary Session I
Nobel Laureate
Dr. Ferid Murad, M.D., Ph.D.
UTHSC, at Houston, Medical School

Plenary Session II
Nobel Laureate
Dr. Eric Chivian, M.D.
Harvard Medical School

Highlights:

Two (2) Nobel Laureate Plenary Sessions
Six (6) Panel Sessions
25+ Distingusihed Speakers

Two (2) Company Presentation Sessions
Many networking breaks
Private VIP Cocktail reception

Conference Website: http://bio.saeclub.com

Presenting Companies (sample): the few companies chosen are what we call “imminently fundable” and passed our rigorous screening process.

*
Company A- Drug discovery and drug development company with drugs in Pre-clinical trials and Phase II.. So far it has raised over $25 million and is seeking $30 million in Series C funding.
*
Company B - Computational drug design and drug development company expected to file 3 INDs within the next year. Has raised $87.8 million and is currently seeking an additional $25 million.
*
Company C - Company developing topical products for viral, fungal, and bacterial infections. Have completed several Phase I and Phase II trials. So far has raised $2.6 million and is currently seeking $15 million.

Delegates Already Registered To Attend (sample):

CEO - Digital Bio (South Korea); CEO - Med Discovery (Switzerland); Director - Exgenis (UK); CEO - Congenix (Russia, trying for visa); Managing Director- The Carlyle Group; Professor Of Medicine- Columbia University; General Partner- EDF Ventures; Partner - Phillips Nizer, LLP; General Partner- MPM Capital; Bioinformatics Executive-Microsoft; General Partner- Flagship Ventures; President - Digital Bio Technology; Managing Director-Catalyst Health and Technology Partners; CEO - PKPD; Managing Director, Life Sciences- Hercules Technology Growth Capital; CFO.- Serenex, Inc.; Managing General Partner- Boston Millennia Partners; Chairman, President & CEO - Locus Pharmaceuticals, Inc; Managing Partner- Cross Atlantic Partners; Executive- Equinox Group; General Partner- EuclidSR Partners; Controller -Fast Track Systems, Inc.; General Partner- Seaflower Ventures; Director - Gerson Lehrman Group; General Partner- Domain Associates, LLC; Director- Digital Bio Technology; General Partner- Spray Venture Partners; Startup Executive (M.D., Ph.D) - Harvard Medical School; General Partner- SV Life Sciences Advisers; Managing General Partner- Boston Millennia Partners; Managing Partner/ Founder- Arboretum Ventures; Partner- Davis Wright Tremaine LLP; Partner- Stroock & Stroock & Lavan; Partner- A.M. Pappas & Associates; Partner- MedVenture Associates; President- Janus Pharma; General Partner- New Leaf Venture Partners L.L.C; President & CEO- Serenex, Inc.; President & CEO- BioTrove; Managing Partner- Easton Capital; President & COO- Pharmos Corporation; Principal- The Aurora Funds; Principal- Cannon Design; Principal- Bear Stearns Health Innoventures; Principal- Care Capital; Sr. Planner-Cannon Design; Sr. Vice President- Life Sciences Greenhouse; Sr. Vice President- William Gallagher Associates; Managing Director - Red Abbey Venture Partners; Biotech Entrepreneur - Princeton University; Biotech Entrepreneur - Brandeis University; Tech. Advisor & Patent Agent- Stroock & Stroock & Lavan; Vice President- Cytel Inc.; Vice President- Frazier Healthcare Ventures; VP Bus. Development & Field Operations- BioTrove; Managing Director- Cogene Ventures; VP of Research & Development/ CSO- Locus Pharmaceuticals, Inc; Investment Partner- Mitsui & Co. Venture Partners, Inc; VP, Business Development- Chugai Pharma USA; Managing Director- KBL Healthcare Ventures; CEO - Med Discovery; CEO -Transave Inc.; Partner - Ropes & Gray, LLP; Managing Partner- Ascent Biomedical Ventures; Partner - Davis Wright Tremaine, LLP; CEO - Xcellerex; SVP, Director - Gerson Lehrman Group; Corporate Dev. Exe- Serenex, Inc.;and more.